2 ms·

There is a categorical difference between the OP, in which failure to account for statins creates the observation, and a clinical trial that successfully reduce

There is a categorical difference between the OP, in which failure to account for statins creates the observation, and a clinical trial that successfully reduces mortality even though the event rate in the control arm wasn’t 100%. That difference is so great that there is almost no relationship between those scenarios.

DocSavage 7y ago
You don’t know how many people in the low-cholesterol group were on statins in OP article, correct? And despite you completely downplaying it with “the event rate in the control arm wasn’t 100%”, you don’t know how many people in the high-cholesterol group in asymptomatic studies had zero CAC scores (e.g., 50% from EISNER). In both cases you are drawing a conclusion based on incomplete partitioning. There’s also no consideration of non-CVD mortality and especially morbidity in most of these studies. Despite your unequivocal statement that (all) statins are safe, there’s still a lot we don’t know about long-term use including effects on cognition (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830056/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830056/).